Skip to content

News Category: Health & Medical

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

By asianet

Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The MAT2A program is part of Insilico’s growing portfolio of synthetic lethality assets in development. MTAP … Continued

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

By asianet

— Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children HOYA Vision Care ( https://c212.net/c/link/?t=0&l=en&o=3525428-1&h=2929097389&u=https%3A%2F%2Fwww.hoyavision.com%2F&a=HOYA+Vision+Care ), a leader in optical technology innovation, shared the results of a six-year follow-up clinical study ( https://c212.net/c/link/?t=0&l=en&o=3525428-1&h=3417434965&u=https%3A%2F%2Fwww.hoyavision.com%2Fabstract-6-years-result&a=six-year+follow-up+clinical+study ) on its award winning MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology at the Association … Continued

European Stroke Organisation Conference 2022: New study links gut microbiota strains with more severe strokes and poorer post-stroke recovery

By asianet

A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome could be an important factor in stroke risk and outcomes. The study, presented today at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer … Continued

Sun Nuclear Introduces SunSCAN(TM) 3D, Next-Generation Cylindrical Water Scanning System

By asianet

– System to Debut at ESTRO Annual Congress & Upcoming Online Release Event Sun Nuclear Corporation (Sun Nuclear) ( https://c212.net/c/link/?t=0&l=en&o=3522597-1&h=3545425273&u=https%3A%2F%2Fwww.sunnuclear.com%2F&a=Sun+Nuclear+Corporation ), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”), today announced the release of the SunSCAN(TM) 3D cylindrical water scanning system ( https://c212.net/c/link/?t=0&l=en&o=3522597-1&h=2126149412&u=https%3A%2F%2Fwww.sunnuclear.com%2Fproducts%2Fsunscan3d&a=SunSCAN%E2%84%A2+3D+cylindrical+water+scanning+system ) for linear accelerator (linac) commissioning, beam scanning and annual … Continued

Mediso acquires nuclear medicine supplier Bartec Technologies

By asianet

Mediso Ltd today announced the acquisition of Bartec Technologies Ltd, UK based company specialised in the supply, installation and support of Nuclear Medicine and Molecular Imaging equipment and accessories. The acquisition strengthens Mediso’s market position in the UK and Ireland. Financial details of the acquisition were not disclosed. Mediso Medical Imaging Systems with headquarters in … Continued

Ascensia Diabetes Care Presents News Research Showing that People Uing the Contour(R) Blood Glucose Monitoring System and App Experience Few Out-Of-Target Blood Glucose Levels

By asianet

Ascensia Diabetes Care, a global diabetes care company, maker of CONTOUR(R) blood glucose monitoring (BGM) system portfolio and distributor of the Eversense(R) continuous glucose monitoring (CGM) system, announces a new study demonstrating that people who use the connected CONTOUR(R) BGM systems (BGMS) and CONTOUR(R)DIABETES App (CDA) for at least six months can see a reduced … Continued

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

By asianet

Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ … Continued

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

By asianet

Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio’s protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan. Logo – https://mma.prnewswire.com/media/1803052/Healion_Bio_Logo.jpg Dr. Sina … Continued

Varian Partners with Icon Group to Advance Patient-Centric Solutions

By asianet

– Bringing clinical insights into early product development Varian, a Siemens Healthineers company (Varian), today announced a five-year research and professional services agreement with Icon Group (Icon). Through this agreement, Icon will participate in clinical and technical research programs, product evaluation projects, and clinical consultations with Varian to offer Icon’s clinical expertise and industry perspectives … Continued